Fruit Fiber Consumption Specifically Improves Liver Health Status in Obese Subjects Under Energy Restriction

Overview

Journal Nutrients

Date 2017 Jun 29

PMID 28657604

Citations 32

Authors

Irene Cantero

Itziar Abete

J Ignacio Monreal

J Alfredo Martinez

M Angeles Zulet

Affiliations

Soon will be listed here.

Abstract

The prevalence of non-alcoholic-fatty-liver-disease (NAFLD) is associated with obesity, diabetes, and metabolic syndrome (MS). This study aimed to evaluate the influence of two energy-restricted diets on non-invasive markers and scores of liver damage in obese individuals with features of MS after six months of follow-up and to assess the role of fiber content in metabolic outcomes. Seventy obese individuals from the RESMENA (Reduction of Metabolic Syndrome in Navarra) study were evaluated at baseline and after six months of energy-restricted nutritional intervention (American Heart Association (AHA) and RESMENA dietary groups). Dietary records, anthropometrical data, body composition by dual energy X-ray absorptiometry (DXA), and routine laboratory measurements were analyzed by standardized methods. Regarding liver status, cytokeratin-18 fragments and several non-invasive scores of fatty liver were also assessed. The RESMENA strategy was a good and complementary alternative to AHA for the treatment of obesity-related comorbidities. Participants with higher insoluble fiber consumption (≥7.5 g/day) showed improvements in fatty liver index (FLI), hepatic steatosis index (HIS), and NAFLD liver fat score (NAFLD_LFS), while gamma-glutamyl transferase (GGT) and transaminases evidenced significant improvements as a result of fruit fiber consumption (≥8.8 g/day). Remarkably, a regression model evidenced a relationship between liver status and fiber from fruits. These results support the design of dietary patterns based on the consumption of insoluble fiber and fiber from fruits in the context of energy restriction for the management of obese patients suffering fatty liver disease.

Citing Articles

Gut microbiota involvement in the effect of water-soluble dietary fiber on fatty liver and fibrosis.

Sato S, Iino C, Chinda D, Sasada T, Soma G, Tateda T Biosci Microbiota Food Health. 2025; 44(1):49-57.

PMID: 39764489 PMC: 11700550. DOI: 10.12938/bmfh.2024-046.

Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC).

Misceo D, Mocciaro G, DAmore S, Vacca M Nutr Metab (Lond). 2024; 21(1):112.

PMID: 39716321 PMC: 11668039. DOI: 10.1186/s12986-024-00871-3.

Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease.

Lodge M, Dykes R, Kennedy A Biomolecules. 2024; 14(7).

PMID: 39062559 PMC: 11274671. DOI: 10.3390/biom14070845.

Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist.

Millan-Rodriguez C, Castello C, Caballero-Valderrama M, Esquivias G Eur Cardiol. 2024; 18:e64.

PMID: 38213666 PMC: 10782421. DOI: 10.15420/ecr.2023.22.

The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.

Biciusca T, Stan S, Balteanu M, Cioboata R, Ghenea A, Danoiu S Diagnostics (Basel). 2023; 13(21).

PMID: 37958212 PMC: 10649095. DOI: 10.3390/diagnostics13213316.

References

Van Horn L, Carson J, Appel L, Burke L, Economos C, Karmally W . Recommended Dietary Pattern to Achieve Adherence to the American Heart Association/American College of Cardiology (AHA/ACC) Guidelines: A Scientific Statement From the American Heart Association. Circulation. 2016; 134(22):e505-e529. DOI: 10.1161/CIR.0000000000000462. View

Silaghi C, Silaghi H, Colosi H, Craciun A, Farcas A, Cosma D . Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. Clujul Med. 2016; 89(1):82-8. PMC: 4777473. DOI: 10.15386/cjmed-544. View

Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J . The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017; 16(1):15. PMC: 5248473. DOI: 10.1186/s12944-017-0409-6. View

Loomba R, Sanyal A . The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11):686-90. DOI: 10.1038/nrgastro.2013.171. View

Heymsfield S, Wadden T . Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3):254-266. DOI: 10.1056/NEJMra1514009. View

Thoma C, Day C, Trenell M . Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2011; 56(1):255-66. DOI: 10.1016/j.jhep.2011.06.010. View

Kantartzis K, Rettig I, Staiger H, Machann J, Schick F, Scheja L . An extended fatty liver index to predict non-alcoholic fatty liver disease. Diabetes Metab. 2017; 43(3):229-239. DOI: 10.1016/j.diabet.2016.11.006. View

Holscher H . Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017; 8(2):172-184. PMC: 5390821. DOI: 10.1080/19490976.2017.1290756. View

Lopez-Legarrea P, de la Iglesia R, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L . Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: the RESMENA randomized controlled trial. Nutr Metab (Lond). 2013; 10(1):22. PMC: 3584921. DOI: 10.1186/1743-7075-10-22. View

10.

Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I . Liver fibrosis in overweight patients. Gastroenterology. 2000; 118(6):1117-23. DOI: 10.1016/s0016-5085(00)70364-7. View

11.

Kobayashi Y, Tatsumi H, Hattori M, Sugiyama H, Wada S, Kuwahata M . Comparisons of dietary intake in Japanese with non-alcoholic fatty liver disease and type 2 diabetes mellitus. J Clin Biochem Nutr. 2016; 59(3):215-219. PMC: 5110943. DOI: 10.3164/jcbn.16-7. View

12.

de Mello V, Laaksonen D . [Dietary fibers: current trends and health benefits in the metabolic syndrome and type 2 diabetes]. Arq Bras Endocrinol Metabol. 2009; 53(5):509-18. DOI: 10.1590/s0004-27302009000500004. View

13.

Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, Kajor M, Chwist A, Milkiewicz P . Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010; 10:67. PMC: 2905324. DOI: 10.1186/1471-230X-10-67. View

14.

Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T . A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013; 59(3):550-6. DOI: 10.1016/j.jhep.2013.04.027. View

15.

Dai D, Chang Y, Chen Y, Chen S, Yu S, Guo X . Visceral Adiposity Index and Lipid Accumulation Product Index: Two Alternate Body Indices to Identify Chronic Kidney Disease among the Rural Population in Northeast China. Int J Environ Res Public Health. 2016; 13(12). PMC: 5201372. DOI: 10.3390/ijerph13121231. View

16.

Hodson L, Banerjee R, Rial B, Arlt W, Adiels M, Boren J . Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. J Am Heart Assoc. 2015; 4(10):e002258. PMC: 4845132. DOI: 10.1161/JAHA.115.002258. View

17.

Perez-Cornago A, Lopez-Legarrea P, de la Iglesia R, Lahortiga F, Martinez J, Zulet M . Longitudinal relationship of diet and oxidative stress with depressive symptoms in patients with metabolic syndrome after following a weight loss treatment: the RESMENA project. Clin Nutr. 2013; 33(6):1061-7. DOI: 10.1016/j.clnu.2013.11.011. View

18.

Perez-Cornago A, Ramirez M, Zulet M, Martinez J . Effect of dietary restriction on peripheral monoamines and anxiety symptoms in obese subjects with metabolic syndrome. Psychoneuroendocrinology. 2014; 47:98-106. DOI: 10.1016/j.psyneuen.2014.05.003. View

19.

Zolfaghari H, Askari G, Siassi F, Feizi A, Sotoudeh G . Intake of Nutrients, Fiber, and Sugar in Patients with Nonalcoholic Fatty Liver Disease in Comparison to Healthy Individuals. Int J Prev Med. 2016; 7:98. PMC: 4995850. DOI: 10.4103/2008-7802.188083. View

20.

Yang K, Hung H, Lu C, Chang H, Lee L, Huang K . Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance. Sci Rep. 2016; 6:27034. PMC: 4887873. DOI: 10.1038/srep27034. View